Clinical association of miR-155-5p with breast cancer and its relevance for treatment with PARP inhibitors

被引：0

作者：

Pasculli, Barbara ^{[1
]}

Barbano, Raffaela ^{[1
]}

Fontana, Andrea ^{[1
]}

Biagini, Tommaso ^{[1
]}

Di Viesti, Maria Pia ^{[1
]}

Rendina, Michelina ^{[1
]}

Valori, Vanna Maria ^{[1
]}

Morritti, Maria ^{[1
]}

Bravaccini, Sara ^{[2
]}

Ravaioli, Sara ^{[2
]}

Maiello, Evaristo ^{[1
]}

Graziano, Paolo ^{[1
]}

Murgo, Roberto ^{[1
]}

Copetti, Massimiliano ^{[1
]}

Mazza, Tommaso ^{[1
]}

Fazio, Vito Michele ^{[1
]}

Esteller, Manel ^{[3
,4
,5
,6
]}

Parrella, Paola ^{[1
]}

机构：

[1] IRCCS Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy

[2] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy

[3] Josep Carreras Leukaemia Res Inst IJC, Barcelona, Spain

[4] Ctr Invest Biomed Red Canc CIBERONC, Barcelona, Spain

[5] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain

[6] Univ Barcelona, Barcelona, Spain

来源：

CANCER RESEARCH | 2020年 / 80卷 / 16期

关键词：

D O I：

10.1158/1538-7445.AM2020-1422

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1422

引用

页数：2

共 50 条

[31] Circulating miR-155-5p as a Novel Biomarker of Lumbar Degenerative Disc Disease
Divi, Srikanth N.
Markova, Dessislava Z.
Fang, Taolin
Guzek, Ryan
Kurd, Mark F.
Rihn, Jeffrey A.
Hilibrand, Alan S.
Anderson, David Greg
Vaccaro, Alexander R.
Schroeder, Gregory D.
Kepler, Christopher K.
SPINE, 2020, 45 (09) : E499 - E507
[32] lncRNA NORAD promotes the progression of osteosarcoma via targeting of miR-155-5p
Wang, Ye
Zhou, Bin
Yan, Liping
Wu, Jianhui
Xing, Zhijie
Zhang, Shaochun
Xiang, Fusheng
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (06)
[33] A novel SERS-lateral flow assay (LFA) tray for monitoring of miR-155-5p during pyroptosis in breast cancer cells
Lu, Xiaoxia
Lu, Wenlong
Hua, Dong
ANALYTICAL METHODS, 2024, 16 (24) : 3878 - 3894
[34] MiR-155-5p regulates autophagy and apoptosis of glioma cells through RICTOR
Guo, Zhao
Tian, Jing-Jie
Wang, Yao
Jiang, Lei
Chen, Yang
Dai, He-Jun
Wang, Lei
Zhang, Yi
TRANSLATIONAL CANCER RESEARCH, 2024, 13 (10) : 5509 - 5521
[35] NT21MP negatively regulates paclitaxel-resistant cells by targeting miR-155-3p and miR-155-5p via the CXCR4 pathway in breast cancer
Wang, Yueyue
Yan, Lei
Zhang, Lingyu
Xu, Henan
Chen, Tiantian
Li, Yu
Wang, Haifeng
Chen, Sulian
Wang, Wenrui
Chen, Changjie
Yang, Qingling
INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 53 (03) : 1043 - 1054
[36] PARP Inhibitors for Breast Cancer Treatment A Review
Morganti, Stefania
Marra, Antonio
De Angelis, Carmine
Toss, Angela
Licata, Luca
Giugliano, Federica
Taurelli Salimbeni, Beatrice
Berton Giachetti, Pier Paolo Maria
Esposito, Angela
Giordano, Antonio
Bianchini, Giampaolo
Garber, Judy E.
Curigliano, Giuseppe
Lynce, Filipa
Criscitiello, Carmen
JAMA ONCOLOGY, 2024, 10 (05) : 658 - 670
[37] Advances in PARP inhibitors for the treatment of breast cancer
Dizdar, Omer
Arslan, Cagatay
Altundag, Kadri
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (18) : 2751 - 2758
[38] miR-155-5p increases the sensitivity of liver cancer cells to adriamycin by regulating ATG5-mediated autophagy
Yu, Qiu
Xu, Xiao-Ping
Yin, Xin-Min
Peng, Xiang-Qun
NEOPLASMA, 2021, 68 (01) : 87 - 95
[39] An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Cortesi, Laura
Rugo, Hope S.
Jackisch, Christian
TARGETED ONCOLOGY, 2021, 16 (03) : 255 - 282
[40] PARP inhibitors for the treatment and prevention of breast cancer
Vinayak S.
Ford J.M.
Current Breast Cancer Reports, 2010, 2 (4) : 190 - 197

← 1 2 3 4 5 →